Inventor · disambiguated record
Stephen D. Collins
Also filed as: COLLINS STEPHEN · COLLINS STEPHEN D
7 granted patents·13 pending applications·8 citations·filing 2001–2025
78Inventor score
Files withLUNDBECK PHARMACEUTICALS LLC5BISCAYNE NEUROTHERAPEUTICS INC4CLOYD JAMES3XALUD THERAPEUTICS INC3ABBOTT LAB1
Top patents by PatentIndex Score
20 records- 0180US9629797B2Parenteral carbamazepine formulationCLOYD JAMES·Filed 2012·Granted Apr 25, 2017·3 cites·57 claims
- 0279US9770407B2Parenteral carbamazepine formulationLUNDBECK PHARMACEUTICALS LLC·Filed 2013·Granted Sep 26, 2017·2 cites·30 claims
- 0378US11351120B2Use of higher doses of modified release huperzine formulationsSUPERNUS PHARMACEUTICALS INC·Filed 2019·Granted Jun 7, 2022·3 cites·12 claims
- 0467US2024165125A1Novel parenteral carbamazepine formulationLUNDBECK PHARMACEUTICALS LLC·Filed 2023·Application pending·0 cites
- 0566US12502356B2Use of higher doses of modified release huperzine formulationsBISCAYNE NEUROTHERAPEUTICS INC·Filed 2022·Granted Dec 23, 2025·0 cites·14 claims
- 0665US2025295601A1Modified release pharmaceutical compositions of huperzine and methods of using the sameBISCAYNE NEUROTHERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 0764US12311060B2Modified release pharmaceutical compositions of huperzine and methods of using the sameBISCAYNE NEUROTHERAPEUTICS INC·Filed 2021·Granted May 27, 2025·0 cites·34 claims
- 0862US2010204178A1Novel parenteral carbamazepine formulationCLOYD JAMES·Filed 2009·Application pending·0 cites
- 0961US2013072476A1Novel parenteral carbamazepine formulationLUNDBECK LLC H·Filed 2012·Application pending·0 cites
- 1061US2021196623A1Novel parenteral carbamazepine formulationLUNDBECK PHARMACEUTICALS LLC·Filed 2020·Application pending·0 cites
- 1160US2023203053A1Halogenated derivatives of morphinans and uses thereofXALUD THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1259US2022265547A1Parenteral carbamazepine formulationLUNDBECK PHARMACEUTICALS LLC·Filed 2021·Application pending·0 cites
- 1359US2025051412A1Dosing regimen for il-10 encoding expression constructXALUD THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1456US11505556B2Halogenated derivatives of morphinans and uses thereofXALUD THERAPEUTICS INC·Filed 2018·Granted Nov 22, 2022·0 cites·21 claims
- 1555US2018333365A1Modified release pharmaceutical compositions of huperzine and methods of using the sameBISCAYNE NEUROTHERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 1651US2018153797A1Novel parenteral carbamazepine formulationLUNDBECK PHARMACEUTICALS LLC·Filed 2017·Application pending·0 cites
- 1749US2007185054A1Novel parenteral carbamazepine formulationCLOYD JAMES·Filed 2006·Application pending·0 cites
- 1847US2012004225A1Bumetanide, furosemide, piretanide, azosemide, and torsemide analogs, compositions and methods of useWANASKI STEPHEN·Filed 2010·Application pending·0 cites
- 1941US6872734B2Use of tiagabine for treatment of diabetic neuropathy and migraineABBOTT LAB·Filed 2001·Granted Mar 29, 2005·0 cites·2 claims
- 2041US2015335624A1Compositions and methods for using huperzine and analogs thereofINSERO HEALTH INC·Filed 2014·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Stephen D. Collins files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →